In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

In early corporate news, BP Chair Helge Lund announced his intention to resign, and AstraZeneca received EU approval for two different therapies. Here is what you need to know at the London market ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...

AstraZeneca shares have enjoyed moderate gains this year, helping to recover some of last year’s losses. But does it remain a ...

Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...